Compare Chipotle Mexican Grill, Inc. (CMG) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chipotle Mexican Grill, Inc. vs IDEXX Laboratories, Inc. — how do they compare? Chipotle Mexican Grill, Inc. trades at $32.66 (market cap $40.49B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: Chipotle Mexican Grill, Inc. and IDEXX Laboratories, Inc. are close in size by market cap, and Chipotle Mexican Grill, Inc. is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| CMG | IDXX | |
|---|---|---|
Market Cap | $40.49B | $46.22B |
Sector | Consumer Cyclical | Health |
52-Week High | $44.04 | $766.68 |
52-Week Low | $28.17 | $526.44 |
Enterprise Value | $45.24B | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chipotle Mexican Grill (CMG) trades at $32.615, up 1.48% today, but faces headwinds from recent food safety concerns linked to salmonella outbreaks. The stock's technical outlook is bearish, with moving averages signaling selling pressure. Fundamentally, the company reported strong revenue growth to $11.93B in 2025 and a net income margin of 11.42%, though earnings face compression from rising costs. Recent news highlights ongoing litigation investigations and promotional efforts to boost customer engagement.
The investment outlook is mixed; analyst consensus remains bullish with a $42.17 price target, but near-term risks from food safety issues and margin pressures could limit upside. Long-term growth prospects are supported by consistent revenue increases, but investors should monitor resolution of health concerns and cost management.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
